VolitionRx - New platform format; more proof-of-concept data
The last several months were eventful for VolitionRx. The publication of the first ever proof-of-concept data in haematological cancers was the...
621 Views
VolitionRx - Data with product-grade assays expected soon
According to the latest Q319 update, VolitionRx has made progress with proof-of-concept studies with its upgraded Nu.Q assays and expects to start...
818 Views
VolitionRx - Executive interview
Volition is a multinational life sciences company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers...
752 Views
VolitionRx - Platform upgrades and busy 2019
VolitionRx's latest Q318 results announcement provided an update on the progress across its established R&D projects and added more detail to...
44 Views
VolitionRx - Shifts in US CRC screening; major catalysts in H2
VolitionRx has broad R&D programme and expects to announce major milestones in the coming months, culminating with CE marking and launch of...
51 Views